Dashboard
Manage Tickers

EWTXEdgewise Therapeutics, Inc.

Nasdaq edgewisetx.com


$ 17.14 $ 0.25 (1.45 %)    

Thursday, 12-Sep-2024 09:59:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.26 $ -0.37 (-0.08 %)
DIA $ 408.12 $ -1.34 (-0.33 %)
SPY $ 553.60 $ -1.39 (-0.25 %)
TLT $ 100.46 $ 0.09 (0.09 %)
GLD $ 235.35 $ 0.71 (0.3 %)
$ 16.85
$ 16.89
-- x --
$ 17.17 x 100
$ 16.89 - $ 17.14
$ 5.12 - $ 23.50
447,266
na
1.58B
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wedbush-reiterates-outperform-on-edgewise-therapeutics-maintains-31-price-target
Wedbush Reiterates Outperform on Edgewise ...
08/16/2024 16:39:47

Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $31 price target.

jp-morgan-maintains-overweight-on-edgewise-therapeutics-raises-price-target-to-31
JP Morgan Maintains Overweight on Edgewise...
08/12/2024 14:12:01

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target f...

edgewise-therapeutics-q2-eps-034-beats-036-estimate
Edgewise Therapeutics Q2 EPS $(0.34) Beats...
08/08/2024 12:42:42

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of...

rbc-capital-reiterates-outperform-on-edgewise-therapeutics-maintains-32-price-target
RBC Capital Reiterates Outperform on Edgew...
07/25/2024 15:46:15

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price...

rbc-capital-reiterates-outperform-on-edgewise-therapeutics-maintains-32-price-target
RBC Capital Reiterates Outperform on Edgew...
07/10/2024 13:31:27

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price...

jp-morgan-maintains-overweight-on-edgewise-therapeutics-raises-price-target-to-30
JP Morgan Maintains Overweight on Edgewise...
07/09/2024 15:04:59

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target f...

piper-sandler-maintains-overweight-on-edgewise-therapeutics-maintains-48-price-target
Piper Sandler Maintains Overweight on Edge...
07/01/2024 13:47:04

Piper Sandler analyst Yasmeen Rahimi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and maintains $48 price...

wedbush-reiterates-outperform-on-edgewise-therapeutics-maintains-31-price-target
Wedbush Reiterates Outperform on Edgewise ...
06/26/2024 14:22:00

Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $31 price target.

edgewise-therapeutics-files-for-mixed-shelf-offering-size-not-disclosed
Edgewise Therapeutics Files For Mixed Shel...
05/10/2024 13:10:32

- SEC Filing

edgewise-therapeutics-q1-eps-033-beats-039-estimate
Edgewise Therapeutics Q1 EPS $(0.33) Beats...
05/09/2024 13:05:41

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of...

top-5-health-care-stocks-that-could-sink-your-portfolio-in-q2
Top 5 Health Care Stocks That Could Sink Y...
05/09/2024 12:44:39

edgewise-therapeutics-doses-first-patient-in-phase-2-cirrus-hcm-trial-of-edg-7500-in-obstructive-hypertrophic-cardiomyopathy
Edgewise Therapeutics Doses First Patient ...
05/06/2024 12:12:36

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of t...

edgewise-receives-ema-orphan-drug-designations-for-sevasemten-for-becker-and-duchenne-muscular-dystrophies
Edgewise Receives EMA Orphan Drug Designat...
04/23/2024 12:06:15

rbc-capital-maintains-outperform-on-edgewise-therapeutics-raises-price-target-to-32
RBC Capital Maintains Outperform on Edgewi...
04/22/2024 15:48:19

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...

truist-securities-maintains-buy-on-edgewise-therapeutics-maintains-25-price-target
Truist Securities Maintains Buy on Edgewis...
04/17/2024 17:19:15

Truist Securities analyst Srikripa Devarakonda maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $25 pr...

wedbush-reiterates-outperform-on-edgewise-therapeutics-maintains-26-price-target
Wedbush Reiterates Outperform on Edgewise ...
04/16/2024 14:19:17

Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $26 price target.

edgewise-therapeutics-reports-two-year-topline-results-from-arch-open-label-trial-of-sevasemten-in-adults-with-becker-muscular-dystrophy-sevasemten-was-well-tolerated
Edgewise Therapeutics Reports Two-Year Top...
04/15/2024 20:08:02

"We are pleased by the promising and consistent functional results observed over two years of treatment with sevasemten, to...

rbc-capital-reiterates-outperform-on-edgewise-therapeutics-maintains-28-price-target
RBC Capital Reiterates Outperform on Edgew...
03/12/2024 15:12:53

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $28 price...

piper-sandler-initiates-coverage-on-edgewise-therapeutics-with-overweight-rating-announces-price-target-of-48
Piper Sandler Initiates Coverage On Edgewi...
03/07/2024 10:22:14

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight rating and ...

edgewise-therapeutics-to-present-on-edg-5506-for-the-treatment-of-becker-muscular-dystrophy-at-the-2024-mda-clinical-and-scientific-conference
Edgewise Therapeutics To Present On EDG-55...
02/28/2024 13:11:14

– Company to host an Industry Forum to discuss its approach to protecting and preserving dystrophic muscle featuring key opinio...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION